e - ISSN – 2393-9672

European Journal of Environmental Ecology

Journal homepage: www.mcmed.us/journal/ejee

ROLE OF BIOTECHNOLOGY IN ENVIRONMENTAL DETOXIFICATION OF PHARMACEUTICAL WASTE

Dr. Shireesha K

Dean, GRT Group of Institutions, Tiruttani-631209, Tamilnadu, India

Corresponding Author
Dr. Shireesha K

Email: - shireeshashiri1349@gmail.com

Article Info

Received 16/02/2026; Revised 19/03/2026
Accepted 11/04/2026

ABSTRACT
The rapid growth of the pharmaceutical industry has led to increased production and consumption of drugs, resulting in the continuous release of pharmaceutical residues into the environment. These contaminants, including antibiotics, hormones, analgesics, and cytotoxic agents, persist in aquatic and terrestrial ecosystems, posing significant risks to human health, wildlife, and microbial communities. Conventional wastewater treatment methods are often inadequate for the complete removal of such complex and recalcitrant compounds. In this context, biotechnology has emerged as a promising and sustainable approach for the detoxification of pharmaceutical waste. Biotechnological strategies such as microbial bioremediation, enzymatic degradation, phytoremediation, and the application of genetically engineered microorganisms offer efficient and eco-friendly solutions for the breakdown and transformation of pharmaceutical pollutants into less toxic or non-toxic forms. Advanced bioprocess technologies, including biofilm reactors, membrane bioreactors, and nanobiotechnology, further enhance the efficiency of contaminant removal. Additionally, the integration of omics technologies and synthetic biology has enabled the identification and optimization of metabolic pathways involved in drug degradation. Despite these advancements, challenges such as incomplete mineralization, formation of toxic intermediates, and regulatory concerns remain. This review highlights the critical role of biotechnology in addressing pharmaceutical pollution and underscores its potential in developing sustainable environmental detoxification systems.

Keywords: Pharmaceutical waste; Bioremediation; Enzymatic degradation; Genetically engineered microorganisms.

INTRODUCTION

The exponential growth of the pharmaceutical industry, driven by increasing global healthcare demands and advancements in drug development, has significantly contributed to the accumulation of pharmaceutical waste in the environment. Pharmaceutical residues originate from multiple sources, including manufacturing effluents, hospital discharges, improper disposal of unused medications, and agricultural activities involving veterinary drugs. These contaminants encompass a wide range of chemical classes such as antibiotics, non-steroidal anti-inflammatory drugs, hormones, antineoplastic agents, and personal care products, many of which are designed to be biologically active and chemically stable. As a result, they persist in aquatic systems, soils, and even drinking water sources, leading to ecological imbalances and potential human health hazards. The presence of antibiotics in the environment, for instance, has been linked to the emergence of antimicrobial resistance, while endocrine-disrupting compounds interfere with hormonal systems in wildlife and humans[1]. Conventional physicochemical methods of wastewater treatment, including coagulation, filtration, and chlorination, are often insufficient in completely removing these micro pollutants, primarily due to their complex molecular structures and low biodegradability. Moreover, such methods may generate secondary pollutants or toxic by-products, further complicating environmental management. In response to these limitations, biotechnology has gained considerable attention as an effective and sustainable approach for the detoxification of pharmaceutical waste. Biotechnological interventions utilize living organisms or their enzymatic systems to degrade, transform, or immobilize contaminants into less harmful forms. Microbial bioremediation, employing bacteria, fungi, and algae, plays a pivotal role in metabolizing pharmaceutical compounds through enzymatic pathways such as oxidation, reduction, and hydrolysis. Advances in genetic engineering have enabled the development of genetically modified microorganisms with enhanced degradation capabilities and specificity toward target pollutants. Additionally, phytoremediation leverages plants and their associated rhizosphere microbes to absorb, accumulate, and detoxify pharmaceutical residues from soil and water[2]. Emerging technologies such as membrane bioreactors, biofilm-based systems, and Nano biotechnology have further improved the efficiency and scalability of bioremediation processes. The integration of omics tools, including genomics, proteomics, and metabolomics, has facilitated a deeper understanding of microbial pathways and interactions involved in contaminant degradation, paving the way for optimized and targeted biotechnological solutions. Despite these advancements, several challenges persist, including incomplete degradation, formation of intermediate metabolites with unknown toxicity, and regulatory and safety concerns associated with the release of engineered organisms into the environment. Therefore, continued research and innovation are essential to harness the full potential of biotechnology in mitigating pharmaceutical pollution and ensuring environmental sustainability.[3]

Pharmaceutical Waste and Environmental Concerns

Pharmaceutical waste has emerged as a critical environmental concern due to the increasing production, consumption, and improper disposal of medicinal products worldwide. This waste includes expired drugs, unused medications, manufacturing by-products, and hospital effluents containing active pharmaceutical ingredients (APIs) that are often biologically potent and chemically stable. Unlike conventional pollutants, pharmaceutical compounds are designed to exert specific physiological effects at low concentrations, making their presence in the environment particularly problematic. The persistence of these substances in water bodies, soil, and sediments is attributed to their resistance to degradation and incomplete removal by traditional wastewater treatment systems. Rapid urbanization, population growth, and expanding healthcare access have further intensified the volume of pharmaceutical residues entering the ecosystem[4]. In many developing countries, inadequate waste management infrastructure and lack of awareness contribute significantly to the direct disposal of drugs into water systems. Environmental concerns are further exacerbated by the continuous discharge of low concentrations of pharmaceuticals, leading to chronic exposure rather than acute toxicity. Such exposure can disrupt ecological balance, alter microbial communities, and promote the development of antimicrobial resistance. Additionally, pharmaceutical pollutants can bio accumulate in aquatic organisms, entering the food chain and posing long-term health risks to humans. The issue is particularly alarming for endocrine-disrupting compounds and cytotoxic drugs, which can interfere with hormonal systems and cellular processes even at trace levels[5]. Climate change and environmental stressors may further influence the behavior and fate of pharmaceutical contaminants, increasing their mobility and persistence. Consequently, there is a growing need for sustainable strategies to mitigate pharmaceutical waste and its environmental impact. Biotechnology offers promising solutions by enabling the detoxification and degradation of complex pharmaceutical compounds through biological processes. Addressing pharmaceutical waste is not only essential for environmental protection but also for safeguarding public health and ensuring sustainable development in the face of increasing pharmaceutical consumption[6].

Table 1: Sources of Pharmaceutical Contaminants

Source	Type of Waste	Example Compounds
Pharmaceutical Manufacturing	Manufacturing by-products	Antibiotics, Analgesics
Hospitals	Excreted drugs, unused meds	Hormones, Antineoplastics
Households	Expired/unused medications	OTC drugs, NSAIDs
Veterinary Practices	Veterinary drugs	Anthelmintics, Antibiotics
Agricultural Activities	Runoff from manure	Hormonal drugs, Antibiotics

Sources and Classification of Pharmaceutical Contaminants

Pharmaceutical contaminants originate from diverse sources and can be broadly classified based on their origin, chemical structure, and therapeutic application. Major sources include pharmaceutical manufacturing industries, hospitals, households, veterinary practices, and agricultural activities. Industrial effluents often contain high concentrations of active pharmaceutical ingredients due to production processes, inadequate waste treatment, or accidental discharges. Hospitals and healthcare facilities contribute significantly through excreted drugs, unused medications, and improper disposal of clinical waste. Household contributions arise from the disposal of expired or unused drugs via sewage systems, while veterinary pharmaceuticals used in livestock and aquaculture enter the environment through manure and runoff. Based on therapeutic classification, pharmaceutical contaminants include antibiotics, analgesics, anti-inflammatory drugs, antiepileptic's, hormones, antineoplastic agents, and personal care products. Antibiotics represent a major class due to their widespread use and potential to induce antimicrobial resistance in environmental microbial communities[7]. Hormonal compounds, such as estrogens, are categorized as endocrine-disrupting chemicals due to their ability to interfere with hormonal regulation in organisms. Antineoplastic drugs, used in cancer therapy, are highly toxic and persistent, posing significant ecological risks. From a chemical perspective, pharmaceuticals can be classified into hydrophilic and hydrophobic compounds, influencing their environmental distribution and behavior. Hydrophilic drugs tend to remain in aqueous environments, whereas hydrophobic compounds accumulate in sediments and biological tissues. Additionally, pharmaceuticals may exist as parent compounds, metabolites, or transformation products formed during environmental degradation processes.[8]

Figure 1: Sources and Classification of Pharmaceutical Contaminants

Environmental Impact of Pharmaceutical Residues

The environmental impact of pharmaceutical residues is a growing global concern, primarily due to their persistence, bioactivity, and potential to disrupt ecological systems even at trace concentrations. Once introduced into the environment, these compounds can contaminate surface water, groundwater, soil, and sediments, leading to widespread ecological consequences. Aquatic ecosystems are particularly vulnerable, as wastewater treatment plants often fail to completely remove pharmaceutical residues, allowing them to enter rivers, lakes, and oceans. Chronic exposure to pharmaceuticals can adversely affect aquatic organisms, altering their growth, reproduction, and behavior. For example, exposure to endocrine-disrupting compounds can cause feminization of male fish and reproductive abnormalities, while antibiotics can inhibit microbial activity and disrupt nutrient cycling [9]. The presence of pharmaceutical residues also contributes significantly to the development of antimicrobial resistance, a major public health threat, by promoting the survival and proliferation of resistant bacterial strains in the environment. Terrestrial ecosystems are affected through the application of contaminated sludge and manure, leading to the accumulation of pharmaceuticals in soil and uptake by plants. This can result in phytotoxic effects, reduced crop productivity, and potential entry of contaminants into the food chain. Bioaccumulation and biomagnification of pharmaceutical compounds in organisms further increase the risk to higher trophic levels, including humans. Additionally, pharmaceutical residues can interact with other environmental pollutants, leading to synergistic or antagonistic effects that complicate toxicity assessments[10].

Microbial Bioremediation of Pharmaceutical Waste

Microbial bioremediation is one of the most effective and sustainable approaches for the detoxification of pharmaceutical waste, utilizing the metabolic capabilities of microorganisms to degrade or transform complex drug molecules into less harmful compounds. Various microorganisms, including bacteria, fungi, and algae, possess enzymatic systems that enable them to utilize pharmaceutical compounds as carbon or energy sources. Bacterial species such as Pseudomonas, Bacillus, and Escherichia coli are widely studied for their ability to degrade antibiotics, analgesics, and other pharmaceutical pollutants through metabolic pathways involving oxidation, reduction, and hydrolysis[11]. Fungi, particularly white-rot fungi like Phanerochaete chrysosporium, play a significant role due to their production of extracellular enzymes such as lignin peroxidase, manganese peroxidase, and laccase, which can degrade structurally complex and recalcitrant compounds. Algae also contribute to bioremediation by absorbing and metabolizing pharmaceutical residues, as well as enhancing oxygen levels in aquatic systems, thereby supporting microbial degradation. Microbial bioremediation can occur under aerobic or anaerobic conditions, depending on the nature of the contaminant and environmental conditions. Bio augmentation, the introduction of specific microbial strains, and bio stimulation, the enhancement of native microbial activity through nutrient addition, are commonly employed strategies to improve degradation efficiency. The formation of microbial consortia often enhances biodegradation due to synergistic interactions among different species[12]. However, factors such as pH, temperature, nutrient availability, and contaminant concentration significantly influence microbial activity and degradation rates. Despite its advantages, microbial bioremediation may lead to incomplete degradation or formation of intermediate metabolites with unknown toxicity. Advances in molecular biology and omics technologies have facilitated the identification of genes and pathways involved in pharmaceutical degradation, enabling the development of more efficient and targeted bioremediation strategies. Overall, microbial bioremediation represents a cost-effective, eco-friendly, and versatile solution for managing pharmaceutical waste and reducing its environmental impact[13].

Figure 2: Microbial Bioremediation of Pharmaceutical Waste

Enzymatic Biotransformation of Drug Molecules

Enzymatic biotransformation represents a highly specific and efficient mechanism for the detoxification of pharmaceutical compounds in the environment, utilizing enzymes to catalyze chemical reactions that convert active drug molecules into less toxic, more biodegradable forms. Enzymes such as oxidoreductases, hydrolases, transferases, and leases play a crucial role in modifying the chemical structure of pharmaceuticals through processes including oxidation, reduction, hydrolysis, and conjugation. Among these, cytochrome P450 monooxygenases, laccases, peroxidases, and esterase's are extensively studied for their ability to degrade a wide range of pharmaceuticals, including antibiotics, non-steroidal anti-inflammatory drugs, and endocrine-disrupting compounds. Laccases and peroxidases derived from fungi are particularly effective in breaking down complex aromatic structures due to their broad substrate specificity and ability to function under diverse environmental conditions[14]. Enzymatic processes can be employed in both free and immobilized forms, with immobilization techniques enhancing enzyme stability, reusability, and operational efficiency in industrial applications. Biotransformation often involves sequential reactions that produce intermediate metabolites, which may undergo further enzymatic degradation until complete mineralization is achieved. The integration of enzymatic systems into wastewater treatment processes has shown promising results in enhancing the removal efficiency of persistent pharmaceutical pollutants. Additionally, advances in protein engineering and directed evolution have enabled the development of enzymes with improved catalytic efficiency, substrate specificity, and resistance to environmental stressors[15].

Application of Genetically Engineered Microorganisms (GEMs)

Genetically engineered microorganisms (GEMs) have emerged as a powerful and innovative approach in the field of environmental biotechnology for the detoxification of pharmaceutical waste, offering enhanced specificity and efficiency compared to naturally occurring microbial systems. Through genetic modification techniques such as recombinant DNA technology, metabolic engineering, and synthetic biology, microorganisms can be tailored to possess improved capabilities for degrading complex pharmaceutical compounds. Genes encoding specific degradative enzymes, such as cytochrome P450s, laccases, and hydrolases, can be introduced or overexpressed in host organisms like Escherichia coli, Pseudomonas putida, and Bacillus subtilis, thereby enhancing their metabolic potential. GEMs can also be engineered to withstand harsh environmental conditions, including high concentrations of pollutants, pH fluctuations, and temperature variations, which are commonly encountered in contaminated environments.[16] Additionally, metabolic pathways can be optimized to ensure complete mineralization of pharmaceutical compounds, reducing the accumulation of toxic intermediates. The use of biosensors in GEMs further enables real-time monitoring of contaminant levels, facilitating targeted remediation strategies. Despite their promising potential, the application of GEMs raises significant biosafety and regulatory concerns, particularly regarding their release into natural ecosystems. Horizontal gene transfer, ecological imbalance, and unintended effects on native microbial communities are key issues that must be addressed. Containment strategies, such as the use of immobilized systems, suicide genes, and controlled bioreactor environments, are being developed to mitigate these risks.[17] Advances in genome editing technologies, such as CRISPR-Cas systems, have further expanded the possibilities for precise and efficient genetic modifications, enhancing the applicability of GEMs in environmental detoxification. Overall, GEMs represent a cutting-edge solution for the biodegradation of pharmaceutical pollutants, with the potential to significantly improve the efficiency and sustainability of bioremediation processes when coupled with appropriate safety measures.

Phytoremediation Approaches in Pharmaceutical Detoxification

Phytoremediation is an environmentally friendly and cost-effective strategy that utilizes plants and their associated rhizosphere microorganisms to remove, degrade, or stabilize pharmaceutical contaminants from soil and water systems. This approach is particularly advantageous due to its sustainability, low operational cost, and minimal environmental disturbance compared to conventional remediation methods. Plants such as Typhus latifolia, Phragmites austral is, and Vetiveria zizanioides have demonstrated significant potential in the uptake and accumulation of pharmaceutical compounds, including antibiotics, analgesics, and endocrine disruptors. The process involves several mechanisms, including phytoextraction, phytodegradation, phytostabilization, and rhizodegradation. In phytoextraction, plants absorb contaminants through their roots and translocate them to aerial parts, while phytodegradation involves the enzymatic breakdown of pharmaceuticals within plant tissues.[18] Rhizodegradation is facilitated by root exudates that stimulate microbial activity in the rhizosphere, enhancing the degradation of pollutants. The synergistic interaction between plants and microorganisms plays a crucial role in improving remediation efficiency. Additionally, constructed wetlands employing phytoremediation principles have been widely used for treating pharmaceutical-contaminated wastewater. However, the effectiveness of phytoremediation depends on factors such as plant species, contaminant concentration, environmental conditions, and duration of exposure. Limitations include slow remediation rates, potential accumulation of toxic compounds in plant tissues, and seasonal variability in plant growth. Despite these challenges, advances in genetic engineering and plant biotechnology are being explored to develop transgenic plants with enhanced phytoremediation capabilities. Overall, phytoremediation offers a green and sustainable solution for mitigating pharmaceutical pollution, particularly in low-resource settings and large-scale environmental applications[19].

Bioreactors and Advanced Bioprocess Technologies

Bioreactors and advanced bioprocess technologies play a pivotal role in enhancing the efficiency and scalability of biotechnological approaches for the detoxification of pharmaceutical waste. Bioreactors provide controlled environments that optimize conditions such as temperature, pH, oxygen levels, and nutrient availability, thereby promoting the growth and metabolic activity of microorganisms or enzymatic systems involved in degradation processes. Various types of bioreactors, including batch reactors, continuous flow reactors, membrane bioreactors (MBRs), fluidized bed reactors, and packed bed reactors, are employed depending on the nature of the contaminant and treatment requirements[20]. Membrane bioreactors, in particular, have gained significant attention due to their ability to combine biological treatment with membrane filtration, resulting in high removal efficiency of pharmaceutical residues and improved effluent quality. Biofilm-based systems further enhance degradation by providing a stable environment for microbial communities and increasing biomass retention. Advanced bioprocess technologies also incorporate immobilized enzymes and cells, which improve stability, reusability, and resistance to environmental fluctuations. Integration of automation and real-time monitoring systems allows for precise control and optimization of bioreactor performance. Additionally, hybrid systems combining biological and physicochemical methods, such as advanced oxidation processes, have been developed to achieve complete mineralization of recalcitrant pharmaceutical compounds[21]. Despite their advantages, challenges such as high operational costs, membrane fouling, and maintenance requirements remain significant barriers to widespread implementation. Continuous research and innovation are focused on improving reactor design, reducing costs, and enhancing treatment efficiency. Overall, bioreactors and advanced bioprocess technologies represent a critical component of modern environmental biotechnology, enabling effective and sustainable management of pharmaceutical waste at both laboratory and industrial scales.

Nanobiotechnology in Environmental Remediation

Nanobiotechnology represents a cutting-edge interdisciplinary approach that combines nanotechnology with biological systems to enhance the efficiency of environmental remediation processes, particularly in the detoxification of pharmaceutical waste. Nanomaterials such as nanoparticles, nanofibers, and nanocomposites exhibit unique physicochemical properties, including high surface area, reactivity, and catalytic activity, which make them highly effective in the removal and degradation of pharmaceutical contaminants. When integrated with biological systems, such as enzymes or microorganisms, nanomaterials can significantly improve the stability, activity, and specificity of bioremediation processes. For instance, enzyme immobilization on nanoparticles enhances catalytic efficiency and allows for repeated use, reducing operational costs. Similarly, nanomaterials can facilitate the delivery of contaminants to microbial cells, improving degradation rates [22]. Magnetic nanoparticles enable easy recovery and reuse of catalysts, while carbon-based nanomaterials such as graphene and carbon nanotubes are effective in adsorbing pharmaceutical residues from aqueous environments. Additionally, nanobiotechnology has been applied in the development of biosensors for the detection and monitoring of pharmaceutical pollutants at trace levels. Despite its promising potential, concerns regarding the toxicity, environmental persistence, and bioaccumulation of nanomaterials must be carefully addressed. The development of eco-friendly and biodegradable nanomaterials is an area of active research aimed at minimizing environmental risks. Overall, nanobiotechnology offers innovative and highly efficient solutions for the remediation of pharmaceutical contaminants, with significant potential for integration into existing wastewater treatment systems and large-scale environmental applications.[23]

Integration of Biotechnology with Wastewater Treatment Systems

The integration of biotechnology with conventional wastewater treatment systems represents a significant advancement in addressing the challenges associated with the removal of pharmaceutical contaminants from environmental matrices. Traditional treatment processes, including primary and secondary treatments, are often insufficient in eliminating micropollutants due to their complex chemical structures and resistance to degradation. By incorporating biotechnological approaches such as microbial bioremediation, enzymatic degradation, and biofilm-based systems, wastewater treatment efficiency can be significantly enhanced. Biological treatment processes, including activated sludge systems, trickling filters, and membrane bioreactors, utilize microbial communities to degrade organic pollutants, including pharmaceuticals.

Advanced systems such as sequencing batch reactors and moving bed biofilm reactors further improve treatment efficiency by optimizing microbial activity and retention time[24]. The use of genetically engineered microorganisms and immobilized enzymes within treatment systems offers additional advantages by targeting specific contaminants and improving degradation rates. Constructed wetlands and phytoremediation systems are also integrated into wastewater treatment frameworks, providing sustainable and low-cost solutions for contaminant removal. Hybrid systems combining biological processes with advanced oxidation techniques have shown promising results in achieving complete mineralization of recalcitrant compounds. However, challenges such as operational complexity, cost, and variability in contaminant composition must be addressed for successful implementation. Continuous monitoring and optimization are essential to ensure consistent performance and compliance with regulatory standards. Overall, the integration of biotechnology into wastewater treatment systems offers a comprehensive and sustainable approach for managing pharmaceutical pollution, improving water quality, and protecting environmental and public health[25].

CONCLUSION

The growing concern over pharmaceutical waste and its persistent impact on the environment has necessitated the development of sustainable and efficient detoxification strategies, among which biotechnology has emerged as a highly promising solution. The application of biotechnological approaches, including microbial bioremediation, enzymatic biotransformation, phytoremediation, and the use of genetically engineered microorganisms, offers eco-friendly and cost-effective alternatives to conventional physicochemical treatment methods. These biological systems possess the inherent capability to degrade, transform, or mineralize complex pharmaceutical compounds into less toxic or non-toxic forms, thereby reducing their environmental burden. Advanced tools such as bioreactors, membrane-based systems, and nanobiotechnology have further enhanced the efficiency, scalability, and specificity of these processes, making them suitable for large-scale applications. Additionally, the integration of omics technologies and synthetic biology has provided deeper insights into metabolic pathways and enabled the optimization of biological systems for targeted degradation of pharmaceutical pollutants. Despite these advancements, several challenges remain, including incomplete degradation, formation of potentially harmful intermediates, variability in environmental conditions, and concerns related to biosafety and regulatory compliance, particularly in the case of genetically modified organisms.

REFERENCES

1. Kumirska, J. (2020). Special issue “Pharmaceutical residues in the environment.” *Molecules*, 25, 2941.
2. Yurdakok-Dikmen, B., Tresnakova, N., Filazi, A., & Faggio, C. (2023). Biological wastewater treatment systems for the biodegradation and detoxification of pharmaceuticals. In *CRC* (pp. 65–86).
3. Eswaran, A., Rajagopal, P., Veeraraghavan, V. P., & Jayaraman, S. (2025). Unleashing the power of omics. In *CRC* (pp. 129–139).
4. Mashchenko, Z. E., Voronin, A. V., & Russkikh, Y. M. (2025). БИОТЕХНОЛОГИЧЕСКИЕ МЕТОДЫ УТИЛИЗАЦИИ ЛЕКАРСТВЕННЫХ СРЕДСТВ. In *All Russian Scientific Research Institute Of Medicinal Aromatic Plants* (pp. 199–203).
5. Islam, I. U., Qurashi, A. N., Adnan, A., Ali, A., Malik, S., Younas, F., et al. (2025). Bioremediation and adsorption: Strategies for managing pharmaceutical pollution in aquatic environments. *Water Air Soil Pollut*, 236.
6. Cobongela, S. Z. Z. (2023). Bioremediation of pharmaceutical waste. In *Bentham Science* (pp. 303–328).
7. Mondal, S., Roy Chowdhury, S., Amatha, S., Gautam, M. K., & Das, R. (2024). Effects of emerging pharmaceutical contaminants on humans. In *CRC* (pp. 124–148).
8. Gałązka, A., & Jankiewicz, U. (2022). Endocrine disrupting compounds (Nonylphenol and Bisphenol A)—Sources, harmfulness, and laccase-assisted degradation in the aquatic environment. *Microorganisms*, 10, 2236.
9. Shi, W.-J., Yao, L., & Zhao, J.-L. (2023). Ecotoxicological and risk assessment of pharmaceutical chemicals in the aquatic environment. In *CRC* (pp. 175–185).
10. Zampelli, S., & Verna, R. (2025). Environmental pollution from pharmaceuticals. *Life*, 15, 1341.
11. Srinivasan, K., Hariharapura, R. C., & Mallikarjuna, S. V. (2025). Pharmaceutical waste management through microbial bioremediation. *Environ Monit Assess*, 197, 488.
12. Dudhagara, D. R., Javia, B. M., & Vala, A. K. (2023). Exploiting marine fungi in the removal of hazardous pollutants and biomass valorisation. In *Springer* (pp. 117–146).
13. Vithalani, P., Mahla, P., Padhiar, J., Bhanushali, U., & Bhatt, N. (2025). New dimensions and innovations in microbes and nanoconjugate-based bioremediation technology. 147–170.

14. Al-Harrasi, A., Bhatia, S., & Khan, A. (2024). Introduction to pharmaceutical biotechnology, Volume 2 (Second edition). *Institute Of Physics*.
15. Ölçücü, G., Klaus, O., Jaeger, K.-E., Drepper, T., & Krauss, U. (2021). Emerging solutions for in vivo biocatalyst immobilization: Tailor-made catalysts for industrial biocatalysis. *ACS Sustainable Chem Eng*, 9, 8919–8945.
16. Shukla, A. K., Yadav, V. K., Yadav, V. P., Shukla, A., & Kanaujia, K. A. (2025). Application of synthetic biology in the bioremediation of pharmaceutical waste. *IJNRPH*, 31–40.
17. Apollon, W., Flores-Breceda, H., Méndez-Zamora, G., Gómez-Leyva, J. F., Luna-Maldonado, A. I., & Kamaraj, S.-K. (2022). Importance of genetically engineered microbes (GEMs) in bioremediation of environmental pollutants. In *CRC* (pp. 203–219).
18. Bhatt, P., Ganesan, S., Santhose, I., & Durairaj, T. (2021). Phytoremediation as an effective tool to handle emerging contaminants. *Physical Sciences Reviews*, 8, 2321–2340.
19. Mishra, S., Mulla, S. I., Saha, S., Kharat, A. S., More, N., & Bharagava, R. N. (2020). Involvement of synergistic interactions between plant and rhizospheric microbes for the removal of toxic/hazardous contaminants. In *Springer Singapore* (pp. 223–238).
20. Ghoshal, G. (2022). Bioreactors for the production of industrial chemicals and bioenergy recovery from waste. 241–262.
21. Bhattacharyya, A., Liu, L., Lee, K., & Miao, J. (2022). Review of biological processes in a membrane bioreactor (MBR): Effects of wastewater characteristics and operational parameters on biodegradation efficiency when treating industrial oily wastewater. *JMSE*, 10, 1229.
22. Suresh, A., & Abraham, J. (2022). Use of nanoparticles in bioremediation of pharmaceutical compounds. In *CRC* (pp. 219–233).
23. Muthu Meenakshi, M., Annasamy, G., Krishnan, S., Hema Brindha, M., & Narasimhan, A. K. (2023). Engineered magnetic nanoparticles as environmental remediation agents. In *Royal Society of Chemistry* (pp. 163–192).
24. Sharma, A., Mittal, V., & Sharma, D. (2025). Emerging biotechnological methods for industrial wastewater treatment. In *IGI Global* (pp. 81–108).
25. Oyebade, T., & Adekoya, O. (2022). Integration of electrochemical oxidation and photocatalysis for treating pharmaceutical residues in wastewater under varying environmental conditions. *GSC Biol Pharm Sci*, 21, 242–260.